BioCentury | May 18, 2018
Finance

CellCentric’s magic trio

Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes...
BC Week In Review | May 18, 2018
Financial News

CellCentric raises $26M to advance into the clinic

CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments. Early this summer, CellCentric plans to begin Phase I testing of lead...
BC Extra | May 14, 2018
Financial News

CellCentric raises $26M to advance into the clinic

CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments. Early this summer, CellCentric plans to begin Phase I testing of lead...
BC Innovations | Oct 26, 2017
Translation in Brief

HATs off to epigenetics

Although the epigenetics field is heating up, most compounds on the market and in development are clustered around the same small set of targets. Now, a team led by AbbVie Inc. (NYSE:ABBV) has uncovered an...
BC Extra | Aug 23, 2017
Preclinical News

Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

Preclinical evidence supporting dual inhibition of E1A binding protein p300 (EP300; p300) and CREB binding protein ( CREBBP ; CBP) as an epigenetic strategy for treating prostate cancer is mounting. In a paper published in Cancer...
Items per page:
1 - 5 of 5